Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

Next Previous
Trial Profile

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; FT 500 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Carcinoma; Hodgkin's disease; Lymphoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms Landmark
  • Sponsors Fate Therapeutics

    • Most Recent Events

    • 27 Jan 2023 Status changed from active, no longer recruiting to completed.
    • 05 Oct 2022 According to Fate Therapeutics media release, results from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting 2022.
    • 27 Sep 2022 Planned End Date changed from 1 Jul 2023 to 17 Nov 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top